Clinical Trials

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

Number: NCT02266745
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Phosplatin Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

Number: NCT02420977
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Number: NCT02452008
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Eli Lilly and Company
Sponsor Trial Information
Trial Location(s) and Contact(s)
Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

Number: NCT02516670
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

Number: NCT02526368
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): University of California, San Francisco|American Cancer Society, Inc.|National Cancer Institute (NCI)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression

Number: NCT02555189
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Sidney Kimmel Cancer Center at Thomas Jefferson University|Novartis|Prostate Cancer Clinical Trials Consortium|Thomas Jefferson University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Number: NCT02744287
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Bellicum Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Number: NCT02769962
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer

Number: NCT02809690
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Southern California|National Cancer Institute (NCI)|National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Sponsor Trial Information
Trial Location(s) and Contact(s)
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

Number: NCT02933255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer

Number: NCT02935205
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Mamta Parikh|National Cancer Institute (NCI)|University of California, Davis
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Number: NCT03207867
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Novartis Pharmaceuticals|Novartis
Sponsor Trial Information
Trial Location(s) and Contact(s)
Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

Number: NCT03262103
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Ashutosh Kumar Tewari|Oncovir, Inc.|Icahn School of Medicine at Mount Sinai
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Number: NCT03317392
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Number: NCT03344211
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Southern California|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Number: NCT03361735
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): City of Hope Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Number: NCT03388619
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer

Number: NCT03392181
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Northwestern University|Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Number: NCT03414034
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Cardiff Oncology
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

Number: NCT03437941
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Corcept Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Number: NCT03460977
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Pfizer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Number: NCT03493945
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

Number: NCT03507608
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor Trial Information
Trial Location(s) and Contact(s)
Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma

Number: NCT03556228
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): VM Oncology, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Number: NCT03569280
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Kangpu Biopharmaceuticals, Ltd.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Number: NCT03574571
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Memorial Sloan Kettering Cancer Center|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of HPN424 in Patients With Advanced Prostate Cancer

Number: NCT03577028
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Harpoon Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers

Number: NCT03585114
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Emerson Lim|Columbia University
Sponsor Trial Information
Trial Location(s) and Contact(s)
This Study is to Evaluate OBI-3424 Safe and Effective Treatment Dose in Subjects With Hepatocellular Carcinoma or Castrate Resistant Prostate Cancer

Number: NCT03592264
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): OBI Pharma, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)
MGC018 With or Without MGA012 in Advanced Solid Tumors

Number: NCT03729596
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): MacroGenics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT03751436
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Roswell Park Cancer Institute|AbbVie
Sponsor Trial Information
Trial Location(s) and Contact(s)
SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors

Number: NCT03784677
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy

Number: NCT03824652
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Stephen Freedland|California Walnut Commission|Cedars-Sinai Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery

Number: NCT03824808
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 4
Sponsor(s): University of Missouri-Columbia
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Number: NCT03837353
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): NYU Langone Health|Leap Therapeutics, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Number: NCT03849469
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Xencor, Inc.|ICON Clinical Research
Sponsor Trial Information
Trial Location(s) and Contact(s)
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Number: NCT03850795
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Hinova Pharmaceuticals USA, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Number: NCT03866382
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

Number: NCT03888612
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arvinas Androgen Receptor, Inc.|Arvinas Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
the Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer

Number: NCT03899467
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Suzhou Kintor Pharmaceutical Inc,
Sponsor Trial Information
Trial Location(s) and Contact(s)
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Number: NCT03934840
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Masonic Cancer Center, University of Minnesota
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone

Number: NCT03939689
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Pilot Study of 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU or HDR Therapy

Number: NCT03949517
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Andrei Iagaru|General Electric|Stanford University
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

Number: NCT03972657
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Regeneron Pharmaceuticals
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Number: NCT04032704
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Seagen Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Number: NCT04060394
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Laekna Limited
Sponsor Trial Information
Trial Location(s) and Contact(s)
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Number: NCT04090528
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Wisconsin, Madison|Merck Sharp & Dohme Corp.|Madison Vaccines, Inc|Prostate Cancer Foundation
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

Number: NCT04104893
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): VA Office of Research and Development|Merck Sharp & Dohme Corp.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Safety and Targeting of Anti-hk2 Antibody in mCRPC

Number: NCT04116164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Tomopath Inc.|Invicro|Janssen Research & Development, LLC
Sponsor Trial Information
Trial Location(s) and Contact(s)
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

Number: NCT04116775
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Julie Graff, MD|Merck Sharp & Dohme Corp.|Prostate Cancer Foundation|Johns Hopkins University|Oregon Health and Science University|Portland VA Medical Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described

Number: NCT04122976
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase:
Sponsor(s): Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies

Number: NCT04158245
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Tulane University|Blue Earth Diagnostics
Sponsor Trial Information
Trial Location(s) and Contact(s)
CELLO-1, Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy

Number: NCT04179864
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Epizyme, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Number: NCT04207255
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Medical University of South Carolina|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Number: NCT04253262
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Brown University|Rhode Island Hospital|The Miriam Hospital|Bayer|Clovis Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy

Number: NCT04288336
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Mayo Clinic|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Number: NCT04288687
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Abramson Cancer Center of the University of Pennsylvania
Sponsor Trial Information
Trial Location(s) and Contact(s)
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide

Number: NCT04335682
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Alliance Foundation Trials, LLC.|Bayer
Sponsor Trial Information
Trial Location(s) and Contact(s)
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

Number: NCT04337580
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Wake Forest University Health Sciences|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)

Number: NCT04349501
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Diego
Sponsor Trial Information
Trial Location(s) and Contact(s)
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Number: NCT04363164
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|United States Department of Defense
Sponsor Trial Information
Trial Location(s) and Contact(s)
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Number: NCT04381832
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Arcus Biosciences, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Number: NCT04382898
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): BioNTech SE
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Number: NCT04446117
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Exelixis|Roche-Genentech|Takeda
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

Number: NCT04455750
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy

Number: NCT04471727
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Harpoon Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Number: NCT04471974
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Rahul Aggarwal|Zenith Epigenetics|Merck Sharp & Dohme Corp.|U.S. Army Medical Research and Development Command|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)

Number: NCT04486755
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): University of Maryland, Baltimore
Sponsor Trial Information
Trial Location(s) and Contact(s)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

Number: NCT04514484
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Number: NCT04521686
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Eli Lilly and Company|Loxo Oncology, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Number: NCT04556617
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1|Phase 2
Sponsor(s): Plexxikon
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Number: NCT04564027
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): AstraZeneca
Sponsor Trial Information
Trial Location(s) and Contact(s)
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Number: NCT04592237
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): M.D. Anderson Cancer Center|Janssen Pharmaceutica
Sponsor Trial Information
Trial Location(s) and Contact(s)
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

Number: NCT04597359
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence

Number: NCT04645810
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): University of Rochester
Sponsor Trial Information
Trial Location(s) and Contact(s)
Insulin Resistance Following ADT for Prostate CA

Number: NCT04658849
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): St. Louis University
Sponsor Trial Information
Trial Location(s) and Contact(s)
ARX517 in Subjects With Advanced Solid Tumor

Number: NCT04662580
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Ambrx, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Number: NCT04698564
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Maryland, Baltimore
Sponsor Trial Information
Trial Location(s) and Contact(s)
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

Number: NCT04716725
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of California, San Francisco|Conquer Cancer Foundation|Gateway for Cancer Research|Prostate Cancer Foundation
Sponsor Trial Information
Trial Location(s) and Contact(s)
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer

Number: NCT04725903
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Not Applicable
Sponsor(s): Emory University|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

Number: NCT04731844
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Rochester
Sponsor Trial Information
Trial Location(s) and Contact(s)
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

Number: NCT04743934
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Andrew McDonald|University of Alabama at Birmingham
Sponsor Trial Information
Trial Location(s) and Contact(s)
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors

Number: NCT04768868
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Impact Therapeutics, Inc.|Covance
Sponsor Trial Information
Trial Location(s) and Contact(s)
An Investigational Scan (68Ga-PSMA-11 PET/CT) for the Imaging of Prostate Cancer

Number: NCT04777071
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): University of Washington
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

Number: NCT04842890
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): The New York Proton Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Number: NCT04879940
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute
Sponsor Trial Information
Trial Location(s) and Contact(s)
11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer

Number: NCT04927663
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Michael Evans|U.S. Army Medical Research Acquisition Activity|National Institute of Mental Health (NIMH)|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer

Number: NCT04943536
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Alessa Therapeutics Inc.|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion

Number: NCT04976257
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Ryan Kohlbrenner, MD|Radiological Society of North America|University of California, San Francisco
Sponsor Trial Information
Trial Location(s) and Contact(s)
Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer

Number: NCT04984343
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Weill Medical College of Cornell University|Viewray Inc.|Progenics Pharmaceuticals, Inc.
Sponsor Trial Information
Trial Location(s) and Contact(s)
Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease

Number: NCT05045066
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Mayo Clinic|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Number: NCT05050084
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 3
Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of PRT2527 in Patients With Advanced Solid Tumors

Number: NCT05159518
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): Prelude Therapeutics
Sponsor Trial Information
Trial Location(s) and Contact(s)
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

Number: NCT05160597
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Early Phase 1
Sponsor(s): Jonsson Comprehensive Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer

Number: NCT05169970
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 2
Sponsor(s): Memorial Sloan Kettering Cancer Center
Sponsor Trial Information
Trial Location(s) and Contact(s)
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Number: NCT05215574
PHEN Patient Summary
ClinicalTrials.gov Information
Trial Phase: Phase 1
Sponsor(s): NGM Biopharmaceuticals, Inc
Sponsor Trial Information
Trial Location(s) and Contact(s)

Total: 96 Clinical Trials

PHEN,Inc. © 2022 All rights reserved